author-photo

David Hoffman

AbbVie

7

Papers

20

Citations

Citation Trend

Filter By

Papers (7) Sort By

Journal Conference Others

Abstract 641: Clinical assessment of the bioavailability of venetoclax tablet and powder formulations

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Comparison of dose modification strategies to address expected hematologic toxicities in treatment-naïve higher-risk (HR) MDS patients treated with venetoclax + azacitidine.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Venetoclax and Azacitidine in the Treatment of Patients with Relapsed/Refractory Myelodysplastic Syndrome

2021 Blood
Show All
- Source
- Cite
- Save
Citations (1)
Molecular Responses Are Observed across Mutational Spectrum in Treatment-Naïve Higher-Risk Myelodysplastic Syndrome Patients Treated with Venetoclax Plus Azacitidine

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
MDS-158: Updated Safety and Efficacy of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Treatment-Naïve, Higher-Risk Myelodysplastic Syndromes: Phase 1b Results

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients With Small‐Cell Lung Cancer

2020 Clinical and Translational Science
Show All
- Source
- Cite
- Save
Citations (0)
Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure–response analysis

2016 Cancer Chemotherapy and Pharmacology
Show All
- Source
- Cite
- Save
Citations (19)